Francesco Schettini

Sobre mí

Publicaciones destacadas

• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

  Autores:

  Prat, Aleix; Guarneri, Valentina; Pascual, Tomas; Braso-Maristany, Fara; Sanfeliu, Esther;

  (...)

  Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.

  Ver listado completo de autores

  Referencia: Ebiomedicine 2022.

• Dissecting the biological heterogeneity of HER2-positive breast cancer

  Autores:

  Schettini, F; Prat, A;

  Referencia: Breast 2021.

• Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

  Autores:

  Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

  (...)

  Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

  Ver listado completo de autores

  Referencia: Ebiomedicine 2021.

• Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial

  Autores:

  Schettini, F; Corona, SP; Giudici, F; Bernocchi, O; Generali, D;

  (...)

  Cerra, D; Loddo, M; Williams, GH; Paris, I; Scambia, G.

  Ver listado completo de autores

  Referencia: Frontiers In Oncology 2021.

• Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer

  Autores:

  Schettini, F; Barbao, P; Braso-Maristany, F; Galvan, P; Martinez, D;

  Pare, L; De Placido, S; Prat, A; Guedan, S.

  Referencia: Esmo Open 2021.

• Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis

  Autores:

  Schettini, F; Giuliano, M; De Placido, S; Prat, A; Giudici, F;

  (...)

  Locci, M; Paris, I; Scambia, G; Rescigno, P; Curigliano, G.

  Ver listado completo de autores

  Referencia: European Journal Of Cancer 2021.

• T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

  Autores:

  Schettini, F; De Placido, P; Parola, S; De Placido, S; Giuliano, M;

  (...)

  Lambertini, M; Del Mastro, L; Cognetti, F; Locci, M; Generali, D.

  Ver listado completo de autores

  Referencia: Esmo Open 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Autores:

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Ver listado completo de autores

  Referencia: Lancet Oncology 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Autores:

  Schettini, Francesco; Pascual, Tomas; Conte, Benedetta; Chic, Nuria; Braso-Maristany, Fara;

  (...)

  Osborne, C Kent; Pernas, Sonia; Perou, Charles M; Carey, Lisa A; Prat, Aleix.

  Ver listado completo de autores

  Referencia: Cancer Treatment Reviews 2020.

• Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

  Autores:

  Giuliano, Mario; Schettini, Francesco; Rognoni, Carla; Milani, Manuela; Jerusalem, Guy;

  (...)

  Pistilli, Barbara; Prat, Aleix; Del Mastro, Lucia; Venturini, Sergio; Generali, Daniele.

  Ver listado completo de autores

  Referencia: Lancet Oncology 2019.

Proyectos destacados

• Dissecting the clinicopathological and molecular features of metastatic HER2-low breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Duración: 01/01/2021 - 30/06/2022

• Extracellular vesicles in cancer development, progression and drug resistance: potential biomarkers and therapeutic targets

  Investigador/a principal: Stefania Catalano

  Código: 2017EKMFTN_006

  Duración: 29/08/2019 - 29/08/2022